Literature DB >> 3615345

Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol.

V Hillegaart, S Ahlenius.   

Abstract

Raclopride, a new potential antipsychotic agent blocking central dopamine (D2) receptors, was found to suppress exploratory locomotor activity, treadmill locomotion and conditioned avoidance response in rats. The threshold dose for effects in these test situations was about 0.5 mg/kg intraperitoneally. A considerably higher dose, 16 mg/kg intraperitoneally, was needed to produce maximal catalepsy. Maximal effects were obtained within 1-2 hrs and the duration of the effect was 2-8 hrs, depending on the test situation. The behavioural profile of raclopride is different from the classic antipsychotic haloperidol, blocking central dopamine (DA) receptors, as well as from the partial DA agonist preclamol, which inhibits central DA neurotransmission by activating DA autoreceptors. Thus, although similar to haloperidol in other respects, comparatively high doses of raclopride are needed to produce catalepsy, indicating less propensity to produce severe extrapyramidal side effects. Raclopride and preclamol are about equipotent in suppressing exploratory locomotor activity. However, raclopride is more potent than preclamol in suppressing treadmill locomotion, conditioned avoidance behaviour and catalepsy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3615345     DOI: 10.1111/j.1600-0773.1987.tb01525.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  16 in total

1.  Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses.

Authors:  Devin Mueller; Christian Bravo-Rivera; Gregory J Quirk
Journal:  Biol Psychiatry       Date:  2010-12-01       Impact factor: 13.382

2.  Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat.

Authors:  M L Wadenberg
Journal:  J Neural Transm Gen Sect       Date:  1992

3.  Effects of selective dopamine D1 and D2 antagonists on male rat sexual behavior.

Authors:  S Ahlenius; K Larsson
Journal:  Experientia       Date:  1990-10-15

4.  Reinstatement of cocaine seeking in rats by the pharmacological stressors, corticotropin-releasing factor and yohimbine: role for D1/5 dopamine receptors.

Authors:  Z J Brown; D A Kupferschmidt; Suzanne Erb
Journal:  Psychopharmacology (Berl)       Date:  2012-06-17       Impact factor: 4.530

5.  Effects of D2 dopamine receptor blockade with raclopride on intracranial self-stimulation and food-reinforced operant behaviour.

Authors:  S Nakajima; J D Baker
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  The role of dopaminergic transmission through D1-like and D2-like receptors in amphetamine-induced rat ultrasonic vocalizations.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-09-28       Impact factor: 4.530

7.  Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy.

Authors:  M L Wadenberg; S Ahlenius
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  Neuroplasticity of dopamine circuits after exercise: implications for central fatigue.

Authors:  Teresa E Foley; Monika Fleshner
Journal:  Neuromolecular Med       Date:  2008-02-15       Impact factor: 3.843

9.  Effects of dopamine D-1 and D-2 antagonists on decision making by rats: no reversal of neuroleptic-induced attenuation by scopolamine.

Authors:  T Ljungberg; M Enquist
Journal:  J Neural Transm Gen Sect       Date:  1990

10.  Differential effects of the selective D2-antagonist raclopride in the nucleus accumbens of the rat on spontaneous and d-amphetamine-induced activity.

Authors:  R van den Boss; A R Cools; S O Ogren
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.